Topiramate in migraine prophylaxis.
This paper reviews results of placebo-controlled trials on topiramate (TPM) prophylaxis in migraine patients, and discusses issues regarding the use of this medication in clinical practice. Data from well conducted double-blind controlled trials and from a comparative trial show that TPM is effective against migraine, confirming the experience of physicians in various countries. Lack of major contraindications, high responder rate, good tolerability at the target dose (100 mg/day) following slow titration, and lack of weight gain make TPM one of the most effective and well accepted drugs for migraine prophylaxis.
D'Amico
D
D
U.O. Cefalee e Malattie Cerebrovascolari, C. Besta National Neurological Institute, Via Celoria 11, I-20133, Milan, Italy. damicodo@tiscali.it
Grazzi
L
L
Usai
S
S
Moschiano
F
F
Bussone
G
G
D000927:Anticonvulsants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D000077236:Topiramate
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose